[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,55,82,114,141,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100625207","this-study-investigates--hydroxy--methylbutyrate-hmb-and-2-hydroxybenzylamine-2-hoba-when-administered-either-individually-or-in-combination-contributes-to-an-increased-quality-of-health-specifically-improving-muscular-strength-and-cognitive-functioning-in-adults-over-the-age-of-65-100625207",false,"NCT07419633","This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65.","The Effects of Beta-Hydroxy-Beta-methylbutyrate (HMB) and\u002For 2-hydroxybenzylamine (2-HOBA) on Markers of Health Span in Older Adults. A Randomized Control Trial.","H2AGE","Inclusion Criteria:\n\n•. 65 years of age\n\n* English or French speaking\n* Females not of childbearing potential\n* Willing to maintain current lifestyle and dietary habits, including level of physical activity, allowed medication\u002Fsupplements habits for the duration of the study\n\nExclusion Criteria:\n\n* Known cardiac diseases, known arterial fibrillation, hepatic diseases, immune diseases (e.g. Individuals with an acute infectious disease, autoimmune disease or are immune compromised), ulcers, asthma, gout, severe anemia, hay fever, nasal polyps.\n\n  * Chronic kidney disease \\[estimated glomerular filtration rate (GFR) \\\u003C 35 mL\u002Fmin\\].\n  * Neurological injury\u002Fdisorder with significant persistent neurological or functional deficit (e.g., stroke with hemiparesis, spinal cord injury, muscular dystrophy, myopathy, myasthenia gravis, Parkinson's disease, peripheral polyneuropathy).\n  * Neuropsychological condition and\u002For cognitive impairment that, in the QI's opinion, could interfere with study participation\n  * History of confirmed chronic obstructive pulmonary disease with a severity grade \\> 2 on the Medical Research Council Dyspnea Scale.\n  * Uncontrolled hypothyroidism or hyperthyroidism. Hypothyroid patients who have changed their dose of hormone replacement therapy in the 6 weeks before screening are not eligible.\n  * Underlying muscle diseases, including a history of or currently active myopathy (e.g., dermatomyositis, polymyositis, etc.) or muscular dystrophies.\n  * Confirmed rheumatoid arthritis, acquired immunodeficiency syndrome (AIDS), type 1 or type 2 diabetes mellitus.\n  * History of cancer in the last 6 months.\n  * Not on any medications including NHPs\u002Fliving with medical conditions that would compromise the study outcome or the safety of the research participant.\n  * Known allergy to study medication or its components (non-medicinal ingredients).\n  * Allergy to aspirin\u002Fsalicylate or if using other drugs containing acetylsalicylic acid or other salicylates and a history of ASA-sensitive asthma\u002Fbronchospasm\n\nThe following list of medications\u002FNHPs will be excluded (and weaned as seen necessary by the study physician) prior to and during the study:\n\n* Participants on newly initiated cholesterol-lowering medication will be excluded. Those on stable regimens for ≥3 months will be included and will be monitored for potential interactions as per the HMB monograph.\n* Medications associated with muscle weakness or immune effects (i.e., oral glucocorticoids).\n* Medications or supplements affecting skeletal muscle metabolism or weight including: Use of MAO-I's (monoamine oxidase inhibitors), additional consumption of 2-HOBA, Vitamin D or HMB, anabolic steroids, selective androgen receptor modulators (SARMs), corticosteroids, GLP-1s, or other weight loss medications).\n* Excessive protein supplementation (i.e., \\>2.0 g\u002Fkg\u002Fday).\n* All participants must be on a stable dose of allowed supplements\u002Fmedications for at least 3 months prior to enrollment. All concomitant therapies will be documented.\n\nNon-pharmacological interventions that could influence study outcomes (e.g., pulmonary rehabilitation, structured exercise programs) will not be permitted.\n\nParticipants undergoing such therapies will be excluded. Any new interventions started during the study must be reported and if judged inappropriate, will result in withdrawal from the trial.",true,"ALL","65 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","In this study, participants will be assigned to receive HMB, 2-HOBA, a combination of both, or a comparison supplement for a set period of time. During the study, participants will attend scheduled visits where researchers will assess muscle strength, physical function, and overall health. Blood samples may be collected to measure markers related to metabolism, inflammation, and oxidative stress. Study staff will also monitor safety and any side effects throughout the study.",[28,29,30,31,32],"Muscle","Cognitive Functioning","Geriatric","Ageing and Geriatric Health","Ageing",[34,28,35,36,37,38,39,40,41],"Health","Cognitive","Memory","natural product","ageing","natural","supplement","preservation","RECRUITING","2026-05-11",{"date":45,"type":46},"2026-05-14","ACTUAL",{"date":48,"type":46},"2026-03-06",{"date":50,"type":22},"2027-02-05",{"name":52,"class":53},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":54},"100631043","comparison-of-the-effects-of-free-weight-and-machine-based-exercises-on-muscular-parameters-100631043","NCT07495540","Comparison of the Effects of Free Weight and Machine-Based Exercises on Muscular Parameters","Comparison of Free Weight and Machine-Based Exercise Effects on Muscular Parameters","Inclusion Criteria:\n\n* Being an individual between the ages of 18-30 years\n* Being physically inactive according to the International Physical Activity Questionnaire short form (\\\u003C600 MET-min\u002Fweek)\n* Residing in Istanbul\n* Voluntary participation in the study.\n\nExclusion Criteria:\n\n* Having a neurological or cardiopulmonary system problem that prevents exercise.\n* Having mental dysfunction.\n* Having an acute musculoskeletal injury which limits exercise participant\n* Being pregnant.\n* Having answered \"YES\" to any question on the Exercise Readiness Questionnaire.","18 Years","30 Years",{"count":65,"type":22},26,[25],"The aim of our study is to compare and investigate the effects of resistance exercises performed with free weights and those performed using machine systems on muscular parameters and neuromuscular control.",[69,70,28,71],"Resistance Exercise","Neuromuscular Adaptations","Adult","NOT_YET_RECRUITING","2026-03-21",{"date":75,"type":46},"2026-03-27",{"date":77,"type":22},"2026-03-23",{"date":79,"type":22},"2026-06-01",{"name":81,"class":53},"Biruni University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":54},"100580438","the-effect-of-vicia-faba-hydrolysate-supplementation-on-muscle-strength-recovery-100580438","NCT06837298","The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery","Inclusion Criteria:\n\n* Males and females 18 - 45 years of age.\n* Willing to fast overnight on the 4 testing occasions.\n* Participants agree to abstain from taking additional supplements throughout the testing period, with particular emphasis placed upon protein-based products (e.g., whey or casein based protein powders; animal derived protein hydrolysates; natural supplements constituted of vegetative protein hydrolysates from rice, fava bean, pea, carrot, spirulina, broccoli, potatoes; marine derived secondary metabolite products or protein hydrolysates including Omega-3 capsules or DHA).\n* Moderately active (exercise 3-5 days per week)\n* Fluent in reading, writing, and speaking English\n* Participants agree to maintain their normal diet and perform only light to moderate exercise for the duration of the study.\n* BMI between 18.5 and 29.9 kg\u002Fm2\n* Participants agree to refrain from consuming alcohol in the 48 hours leading up to a test day.\n* Willingness to complete questionnaires, records and diaries associated with the study and to complete all lab visits.\n* Refrain from any exercise from 48 hours prior to each test or blood draw.\n* Healthy as determined by General Health Questionnaire.\n* Non-smoker\n\nExclusion Criteria:\n\n* Individuals that are glucose-6-phosphate-dehydrogenase deficient. The test product in this study contains fava bean extract which may produce favism in genetically susceptible individuals.\n* Alcohol or drug abuse in the past year.3. Testosterone or estrogen supplementation (not including women on oral contraceptives)\n* Pregnant or nursing or planning to become pregnant.\n* Participation in any other clinical trial in the past 30 days. Participation in any PepsiCo trial in the past 6 months\n* Volunteers with unstable medical conditions.\n* Any complaints that could interfere with the ability to exercise.\n* Individuals who are cognitively impaired or unable to give informed consent.\n* Any co-morbidities interacting with mobility or muscle metabolism of the lower limbs (e.g. arthritis, spasticity \u002F rigidity, all neurological disorders, paralysis).\n* Creatine supplements, corticosteroids, NSAIDS, amino acids, injectible peptides, collagen, and nicotinamide (Vit B3\u002Fniacin).\n* Presence or history of neurological disorders or significant psychiatric illness.\n* Any condition the study investigator believes would interfere with eligibility following the study protocol, effect the study results, or put the subject at undue risk.\n* Participation in resistance or aerobic exercise within 48 hours of the test days.\n* Participation of \\>3 high-intensity exercise sessions per week.\n* Undertake recovery methods such as sea swims, foam rolling, cryotherapy or excessive stretching during days 14-17.\n* Have been in contact with a suspected or confirmed case of COVID-19 in previous 14 days.\n* Are Hepatitis A- or B-positive or have had a sexual partner infected with hepatitis or HIV and not taking medication.\n* Are not employed by, or have a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If you are unsure if a company would be considered a competitor to Gatorade, let the study investigator know the name of the other company and the nature of your relationship to that company before ou sign the informed consent","45 Years",{"count":90,"type":22},76,[25],"To investigate the effect of Vicia faba protein concentrate, a protein derived from Fava bean extract, on delayed onset muscle soreness (DOMS). Participants receive either 2.4g\u002Fday of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 days, 2\u002F3 of them stay on the same treatment and 1\u002F3 of them switch from placebo to PeptiStrong®.",[94,28],"Muscle Damage",[96,97,98,99,100,101,102,103],"DOMS","exercise","damaging","muscle","muscle recovery","vicia faba","fava bean","PeptiStrong","2025-02-14",{"date":106,"type":46},"2025-02-20",{"date":108,"type":46},"2025-02-07",{"date":110,"type":22},"2025-09-30",{"name":112,"class":113},"PepsiCo Global R&D","INDUSTRY",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":54},"100554037","respiratory-rehabilitation-based-on-eccentric-exercice-on-treadmill-after-thoracic-surgery-100554037","NCT06493877","Respiratory Rehabilitation Based on Eccentric Exercice on Treadmill After Thoracic Surgery","Respiratory Rehabilitation Based on Eccentric Exercice on Treadmill After Thoracic Surgery: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Subjects \\>18 years.\n* Thoracic surgery in the previous 75 days\n* Present dyspnea grade 2 - 3 on the mMRC scale.\n* Cognitive and functional level sufficient to understand, learn and carry out the exercise program.\n* Not have contraindications to perform physical training.\n* Active collaborators.\n\nExclusion Criteria:\n\n* Severe intolerance to exertion due to untreated cardiac arrhythmias, ischemia during low intensity exercise (anginas unstable), severe pulmonary hypertension, heart failure (NYHA III or IV)\n* Pulmonary embolism with anticoagulant treatment less than 5 days.\n* Recent cardiovascular events such as congestive heart failure, angioplasties or cardiac surgeries of less than four weeks' duration, valvular alterations requiring surgical correction, myopericarditis, ventricular arrhythmias caused by exercise.\n* Kidney failure requiring dialysis.\n* Patients with uncontrolled bronchospasm due to intrinsic asthma.\n* Patients undergoing post-surgery chemotherapy treatment.\n* Adverse effects that occurred during the development of the treatment.",{"count":122,"type":22},57,[25],"Thoracic surgeries are frequent and pulmonary rehabilitation is essential, since one of the problems that these patients present is dyspnea when performing aerobic exercise, which limits improvement and in some cases causes them to abandon physical exercise. Thanks to carrying out a correct effort retraining program, combining respiratory physiotherapy with therapeutic exercise, patients with respiratory pathologies manage to improve lung capacity and ventilatory mechanics, increase muscle strength and aerobic resistance, prevent long- term complications, reduce fatigue and, ultimately, improve your quality of life.\n\nLikewise, it is important to find the most appropriate type of muscular work that produces more benefits in the short and medium term to optimize our resources.The objective of the study is to demonstrate the effectiveness of eccentric training in patients who have undergone thoracic surgery, in terms of strength, lung capacity, functionality and quality of health in the short and medium term.\n\nFor this purpose, a randomized clinical trial has been designed, with a blinded examiner, following the CONSORT guideline for clinical trials and the ethical principles of the Declaration of Helsinki. A total sample of 57 subjects has been estimated. The study is aimed at patients after scheduled thoracic surgery. A program of 12 group sessions spread over 4 weeks will be carried out. Each of them will last 75 minutes and will include strength and respiratory physiotherapy exercises, common to all subjects.\n\nAerobic interval training will depend on the group assigned: treadmill with negative slope (experimental group), treadmill with positive slope (control group 1) or cycle ergometer (control group 2). On the first and last day of treatment, as well as one month after completing the intervention, the following variables will be measured: thickness, cross-sectional area and ultrasound intensity of the rectus femoris; diaphragmatic excursion and thickness; 6 minute walk test; Borg scale; maximum respiratory pressures; sit-to-stand test; grip strength in both hands; spirometric assessment of FEV1 and SF-12 health quality questionnaire. a",[126,127,28],"Thoracic Surgery","Breathing",[129,130,131],"\"thoracic surgery\"","\"eccentric training\"","\"pulmonary rehabilitation\"","2024-07-09",{"date":134,"type":46},"2024-07-11",{"date":136,"type":22},"2024-09",{"date":138,"type":22},"2027-09",{"name":140,"class":53},"Universidad Europea de Madrid",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":54},"100521840","research-biobank-from-neuromuscular-biopsy-residues-in-the-context-of-care-100521840","NCT06074822","Research Biobank From Neuromuscular Biopsy Residues (in the Context of Care)","Constitution of a Collection of Residues of Neuromuscular Biopsies From Patients Taken as Part of Their Health Care at the Bordeaux University Hospital for Neuromuscular Disease and Use for Research Projects","COLMYONEU","Inclusion criteria\n\n* Patients treated at Bordeaux University Hospital (neurology services, neuropediatrics), rheumatology, medical genetics for suspected neuromuscular disease.\n* Men and women are affected, adults and minors.\n\nExclusion criteria\n\n\\- no exclusion criteria",{"count":150,"type":22},500,"OBSERVATIONAL","Neuromuscular diseases are rare diseases for which significant progress has been made in the context of diagnosis thanks to advances in molecular techniques, but the intimate mechanisms of lesion formation remain poorly understood. Advances in cellular and molecular biology, the development of a few animal models, such as transgenic mice, which make it possible to mimic human pathology have made it possible to better understand the physiopathology of these diseases. However, they still do so very imperfectly and incompletely, making it even more necessary than ever to study diseased human muscle tissue to find new avenues of research or to confirm results obtained by experimentation.\n\nThe purpose of this collection of tissue samples for neuro-muscular purposes is to collect such samples under the best conditions in order to promote basic and translational research on muscle diseases.\n\nThis is why the CHU de Bordeaux wishes to keep the remainders of samples taken as part of the treatment to constitute a collection of biological samples and associated data kept according to quality standards and in compliance with the regulations in force.",[154,28,155],"Neuromuscular Diseases","Nerve","2023-10-05",{"date":158,"type":46},"2023-10-10",{"date":160,"type":46},"2023-06-26",{"date":162,"type":22},"2053-06-25",{"name":164,"class":53},"University Hospital, Bordeaux",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":17,"sex":18,"minAge":173,"maxAge":62,"enrollmentInfo":174,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":54},"100478150","how-are-the-muscles-affected-in-cerebral-palsy-a-study-of-muscle-biopsies-taken-during-orthopaedic-surgery-100478150","NCT05506228","How Are the Muscles Affected in Cerebral Palsy? A Study of Muscle Biopsies Taken During Orthopaedic Surgery.","How Are the Muscles Affected in Cerebral Palsy? A Study of Muscle Biopsies Taken During Orthopaedic Surgery of Children With Cerebral Palsy and Typically Developed Children (Control).","CPTDBiopsy","Inclusion Criteria:\n\n* Children and adolescents undergoing clinically needed orthopaedic surgery\n* with Cerebral Palsy or Acquired Brain Injury\n* Typically developed children and adolescents (control)\n\nExclusion Criteria:\n\n* for CP\u002FABI: Progressive neurological disease, other metabolic or muscle disease\n* for TD (Control): Cerebral Palsy, Acquired Brain injury, other metabolic or muscle diseases","2 Years",{"count":175,"type":22},150,"* Cerebral palsy (CP) is a motor disorder caused by an injury to the immature brain. Even though the brain damage does not change, children with CP will have progressively weaker, shorter and stiffer muscles that will lead to contractures, bony deformations, difficulty to walk and impaired manual ability. An acquired brain injury (ABI) later during childhood, such as after a stroke or an injury, will result in similar muscle changes, and will therefore also be included in this study. For simplicity, these participants will in this text be referred to as having CP.\n* The mechanism for the muscle changes is still unknown. Contractures and the risk for the hips to even dislocate is now treated by tendon lengthening, muscle release and bony surgery. During these surgeries muscle biopsies, tendon biopsies and blood samples will be taken and compared with samples from typically developed (TD) children being operated for fractures, knee injuries, and deformities. The specimens will be explored regarding inflammatory markers, signaling for muscle growth, signaling for connective tissue growth and muscle and tendon pathology. In blood samples, plasma and serum, e.g. pro-inflammatory cytokines and the cytoprotective polypeptide humanin will measured, and will be correlated to the amount humanin found in muscle. With this compound information the mechanism of contracture formation may be found, and hopefully give ideas for treatment that will protect muscle and joint health, including prevention of hip dislocation and general health.\n* The results will be correlated to the degree of contracture of the joint and the severity of the CP (GMFCS I-V, MACS I-V).\n* By comparing muscle biopsies from the upper limb with muscle biopsies from the lower limb, muscles that are used in more or less automated gait will be compared to muscles in the upper limb that are used more voluntarily and irregularly.\n* Muscles that flex a joint, often contracted, will be compared with extensor muscles from the same patient. Fascia, aponeurosis and tendon will also be sampled when easily attainable.",[178,28,179,180],"Cerebral Palsy","Muscle Contracture","Muscle Spasticity",[178,182,183,184,185],"Upper Limb","Lower Limb","Muscle Biopsy","Plasma","2022-08-16",{"date":188,"type":46},"2022-08-18",{"date":190,"type":46},"2002-01-15",{"date":192,"type":22},"2033-12-15",{"name":194,"class":195},"Eva Ponten","OTHER_GOV"]